Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
{window.open('https://sns.qzone.qq.com/cgi-bin/qzshare/cgi_qzshare_onekey?url='+encodeURIComponent(location.href)+'&title='+encodeURIComponent(document.title)+'&summary=&desc=&pics=https://static.prnasia.com/pro/pcom/includes/images/logo-prn-02_PRN.png','_blank','width=650,height=450');})()){kind=link}
 |
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two investor conferences in November 2022 as follows:
Credit Suisse 31st Annual Healthcare Conference 2022
One-on-one meetings: Tuesday, November 8, 2022
Location: Rancho Palos Verdes, CA
Jefferies London Healthcare Conference 2022
Fireside Chat: November 15 at 2:40 pm GMT
One-on-one meetings: Tuesday, November 15, 2022
Location: London, UK
A webcast of the fireside chat will be available on the News and Events section of Gracell's investor website. A replay of the webcast will be available for 30 days following the event.
About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.
Media contact
Marvin Tang
marvin.tang@gracellbio.com
Investor contact
Gracie Tong
gracie.tong@gracellbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-two-upcoming-investor-conferences-301656844.html
Related stocks: NASDAQ:GRCL
Featured Video
Recent Releases
- Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
- Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
- Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
- Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)
- Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
- Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
- Go to MediaRoom
Biotechnology Recent Releases
- Qilian International plans to adjust industrial investment
- GV Announces Cooperation with Top 500 Company in China
- LiveSpo Pharma Emerges as Vietnam's Pioneer at Vitafoods Europe 2024, Unveiling Groundbreaking Research and Product Development to Reduce Antibiotic Use in Digestive and Respiratory Care
- Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
- Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
- Read more
Health Care/Hospital Recent Releases
- More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
- HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market
- Strengthening Bonds in "Momcozy Village": A Comprehensive Review of Momcozy's Mother's Day Campaign
- Qilian International plans to adjust industrial investment
- Sean Ha (Tae Kyoung Ha), the president of USA HoneyNaps, wins an award from South Korea's Ministry of Science and ICT
- Read more
Medical/Pharmaceuticals Recent Releases
- HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market
- Qilian International plans to adjust industrial investment
- GV Announces Cooperation with Top 500 Company in China
- LiveSpo Pharma Emerges as Vietnam's Pioneer at Vitafoods Europe 2024, Unveiling Groundbreaking Research and Product Development to Reduce Antibiotic Use in Digestive and Respiratory Care
- OMRON Healthcare's Presence at Heart Rhythm 2024 in the U.S.
- Read more